- Home
- NUVB vs GDEN Comparison
NUVB vs GDEN Comparison
Compare NUVB & GDEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- GDEN
- Stock Information
- Founded
- NUVB 2018
- GDEN 1998
- Country
- NUVB United States
- GDEN United States
- Employees
- NUVB N/A
- GDEN N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- GDEN Services-Misc. Amusement & Recreation
- Sector
- NUVB Health Care
- GDEN Consumer Discretionary
- Exchange
- NUVB Nasdaq
- GDEN Nasdaq
- Market Cap
- NUVB 837.0M
- GDEN 727.9M
- IPO Year
- NUVB N/A
- GDEN 1999
- Fundamental
- Price
- NUVB $2.75
- GDEN $24.88
- Analyst Decision
- NUVB Strong Buy
- GDEN Buy
- Analyst Count
- NUVB 6
- GDEN 7
- Target Price
- NUVB $8.00
- GDEN $34.86
- AVG Volume (30 Days)
- NUVB 4.6M
- GDEN 237.3K
- Earning Date
- NUVB 08-07-2025
- GDEN 08-07-2025
- Dividend Yield
- NUVB N/A
- GDEN 4.02%
- EPS Growth
- NUVB N/A
- GDEN N/A
- EPS
- NUVB N/A
- GDEN 0.54
- Revenue
- NUVB $14,355,000.00
- GDEN $649,900,000.00
- Revenue This Year
- NUVB $98.78
- GDEN $0.92
- Revenue Next Year
- NUVB $489.71
- GDEN $2.31
- P/E Ratio
- NUVB N/A
- GDEN $45.99
- Revenue Growth
- NUVB 900.35
- GDEN N/A
- 52 Week Low
- NUVB $1.54
- GDEN $22.66
- 52 Week High
- NUVB $3.46
- GDEN $35.49
- Technical
- Relative Strength Index (RSI)
- NUVB 67.35
- GDEN 32.16
- Support Level
- NUVB $2.18
- GDEN $24.20
- Resistance Level
- NUVB $2.55
- GDEN $26.20
- Average True Range (ATR)
- NUVB 0.18
- GDEN 0.90
- MACD
- NUVB 0.03
- GDEN -0.26
- Stochastic Oscillator
- NUVB 82.48
- GDEN 12.62
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.